Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ROMOSOZUMAB-AQQG Cause Ill-defined disorder? 111 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 111 reports of Ill-defined disorder have been filed in association with ROMOSOZUMAB-AQQG. This represents 1.0% of all adverse event reports for ROMOSOZUMAB-AQQG.

111
Reports of Ill-defined disorder with ROMOSOZUMAB-AQQG
1.0%
of all ROMOSOZUMAB-AQQG reports
3
Deaths
80
Hospitalizations

How Dangerous Is Ill-defined disorder From ROMOSOZUMAB-AQQG?

Of the 111 reports, 3 (2.7%) resulted in death, 80 (72.1%) required hospitalization, and 1 (0.9%) were considered life-threatening.

Is Ill-defined disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ROMOSOZUMAB-AQQG. However, 111 reports have been filed with the FAERS database.

What Other Side Effects Does ROMOSOZUMAB-AQQG Cause?

Fall (646) Fracture (612) Arthralgia (517) Injection site pain (490) Bone density abnormal (454) Off label use (419) Hospitalisation (381) Headache (360) Product storage error (348) Death (263)

What Other Drugs Cause Ill-defined disorder?

ACETAMINOPHEN\OXYCODONE (9,780) ACETAMINOPHEN\HYDROCODONE (6,159) TOCILIZUMAB (4,411) RITUXIMAB (4,220) ETANERCEPT (4,202) METHOTREXATE (4,063) ABATACEPT (3,630) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (3,600) LEFLUNOMIDE (3,570) CERTOLIZUMAB PEGOL (3,273)

Which ROMOSOZUMAB-AQQG Alternatives Have Lower Ill-defined disorder Risk?

ROMOSOZUMAB-AQQG vs ROPEGINTERFERON ALFA-2B-NJFT ROMOSOZUMAB-AQQG vs ROPINIROLE ROMOSOZUMAB-AQQG vs ROPIVACAINE ROMOSOZUMAB-AQQG vs ROSIGLITAZONE ROMOSOZUMAB-AQQG vs ROSUVASTATIN

Related Pages

ROMOSOZUMAB-AQQG Full Profile All Ill-defined disorder Reports All Drugs Causing Ill-defined disorder ROMOSOZUMAB-AQQG Demographics